@article{fc52bf94c6a44981a11635d05cb7bd88,
title = "Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases",
abstract = "Objectives: To compare the capacity of ibrutinib (IB) and idelalisib-rituximab (IDELA-R) of prolonging overall survival (OS) as in CLL patients, previously treated with chemotherapy only. Methods: A real-life cohort of 675 cases has been identified and investigated in the database of the groups participating in the study. Results: At an unadjusted univariate analysis, a significant death risk reduction was observed favoring IB (IDELA-R vs IB HR = 0.5, 95% CI = 0.36-0.71) although with some limitations due to the non-randomized and retrospective nature of the study and to the lower number of patients in the IDELA-R group (112 cases) related to the current prescribing practice. To overcome the potential problem of confounding by indication, we adjusted the association between the type of therapy and mortality for all variables significantly associated with OS at Cox univariate analysis. Furthermore, those variables, differently distributed between the two study groups, were introduced into the multivariate Cox model to improve the effectiveness of the analysis. By introducing all these variables into the multiple Cox regression model, we confirmed the protective effect of IB vs IDELA-R (HR = 0.67, 95% CI = 0.45-0.98, P =.04) independent of potential confounders. Conclusions: Although our analysis presents some constraints, that is, the unavailability of additional potential confounders, and the retrospective nature of the study, this observation may be of help for the daily clinical practice, particularly in the absence of randomized trials comparing the two schedules.",
keywords = "Adenine, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Drug Resistance, Neoplasm, Female, Humans, Immunoglobulins, In Situ Hybridization, Fluorescence, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Mutation, Piperidines, Proportional Hazards Models, Purines, Quinazolinones, Recurrence, Retreatment, Rituximab, Treatment Outcome, chronic lymphocytic leukemia, ibrutinib, idelalisib, therapy, Adenine, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Drug Resistance, Neoplasm, Female, Humans, Immunoglobulins, In Situ Hybridization, Fluorescence, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Mutation, Piperidines, Proportional Hazards Models, Purines, Quinazolinones, Recurrence, Retreatment, Rituximab, Treatment Outcome, chronic lymphocytic leukemia, ibrutinib, idelalisib, therapy",
author = "Luca Laurenti and Francesco Morabito and Rossi, {Federica Maria} and Sofia Galimberti and Paolo Monti and Dario Rossi and Robin Foa and Marino Gentile and Fortunato Morabito and Giovanni Tripepi and {Del Poeta}, Giovanni and Mauro, {Francesca Romana} and Gianluigi Reda and Paolo Sportoletti and Marta Coscia and Yair Herishanu and Sabrina Bossio and Marzia Varettoni and Roberta Murru and Annalisa Chiarenza and Andrea Visentin and Adalgisa Condoluci and Riccardo Moia and Daniela Pietrasanta and Giacomo Loseto and Ugo Consoli and Ilaria Scortechini and Rossi, {Francesca Maria} and Antonella Zucchetto and Hamdi Al-Janazreh and Ernesto Vigna and Martino, {Enrica Antonia} and Francesco Mendicino and Ramona Cassin and Graziella D'Arrigo and Sara Galimberti and Angela Rago and Ilaria Angeletti and Annalisa Biagi and {Del Giudice}, Ilaria and Riccardo Bomben and Antonino Neri and Gilberto Fronza and Paola Monti and Paola Menichini and Giovanna Cutrona and Ozren Jaksic and Davide Rossi and {Di Raimondo}, Francesco and Antonio Cuneo and Gianluca Gaidano and Aaron Polliack and Livio Trentin and Robin Fo{\`a} and Manlio Ferrarini and Valter Gattei and Massimo Gentile",
year = "2021",
doi = "10.1111/ejh.13573",
language = "English",
volume = "106",
pages = "493--499",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Oxford : Blackwell",
}